Program
Antioxidants
Also written as “Antioxidants + Clomiphene Citrate”, “Antioxidants + FSH” and “Antioxidants Alone”.
Its studies are mostly in Oligospermia · Infertility, Male, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hamad Medical | 21 open or running | phase 4since Feb 26, 2018 | Feb 26, 2018 | Oct 15, 2027phase 4 · NCT07862725 |
| Vitrolife | 10 open or running | no phasesince Dec 16, 2016 | Dec 16, 2016 | none ahead |
Also a collaborator on its studies: fairhaven-health.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2016First study: no phase study in Culture MediaNew to VitrolifeVitrolife · NCT02999958 · 128 enrolled · Japan
- Feb 26, 2018Hamad Medical's first study: phase 4 study in Infertility, MaleNew to Hamad MedicalHamad Medical · NCT03464656 · 100 enrolled · Qatar
- Sep 29, 2026Phase 4 study in OligospermiaHamad Medical · NCT07862725 · 360 planned · Qatar
Ahead
- Oct 15, 2027Primary completion: phase 4 study in OligospermiaHamad Medical · NCT07862725
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07862725Oligospermia · Qatar | 4 | Not yet recruiting | Hamad Medical | Oct 15, 2027 | 360 |
| NCT03464656Infertility, Male · Qatar | 4 | UNKNOWN | Hamad Medical | Jul 1, 2018 | 100 |
| NCT02999958Culture Media · Japan | – | Completed | Vitrolife | May 2018 | 128 |
How it is read
Names in the registry
- “Antioxidants + Clomiphene Citrate”, 1 entry
- “Antioxidants + FSH”, 1 entry
- “Antioxidants Alone”, 1 entry
- “Antioxidants”, 1 entry
- “Fairhaven Pro for men”, 1 entry
Conditions, from the studies’ own filings
- Oligospermia, 1 study
- Infertility, Male, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.